Prediction/NN
of/IN
Colorectal/JJ
Cancer/NN
Risk/NN
Using/VBG
a/DT
Genetic/JJ
Risk/NN
Score/NNP
:/:
The/DT
Korean/JJ
Cancer/NN
Prevention/NN
Study-II/NN
(/(
KCPS-II/NN
)/)
./.
====================
Colorectal/JJ
cancer/NN
(/(
CRC/NN
)/)
is/VBZ
among/IN
the/DT
leading/VBG
causes/VBZ
of/IN
cancer/NN
deaths/NNS
and/CC
can/MD
be/VB
caused/VBN
by/IN
environmental/JJ
factors/NNS
as/IN
well/RB
as/IN
genetic/JJ
factors/NNS
./.
====================
Therefore/RB
,/,
we/PRP
developed/VBD
a/DT
prediction/NN
model/NN
of/IN
CRC/NN
using/VBG
genetic/JJ
risk/NN
scores/NNS
(/(
GRS/NN
)/)
and/CC
evaluated/VBD
the/DT
effects/NNS
of/IN
conventional/JJ
risk/NN
factors/NNS
,/,
including/VBG
family/NN
history/NN
of/IN
CRC/NN
,/,
in/IN
combination/NN
with/IN
GRS/NN
on/IN
the/DT
risk/NN
of/IN
CRC/NN
in/IN
Koreans/NNS
./.
====================
This/DT
study/NN
included/VBD
187/CD
cases/NNS
(/(
men/NNS
,/,
133/CD
;/:
women/NNS
,/,
54/CD
)/)
and/CC
976/CD
controls/NNS
(/(
men/NNS
,/,
554/CD
;/:
women/NNS
,/,
422/CD
)/)
./.
====================
GRS/NN
were/VBD
calculated/VBN
with/IN
most/JJS
significantly/RB
associated/VBN
single-nucleotide/JJ
polymorphism/NN
with/IN
CRC/NN
through/IN
a/DT
genomewide/NN
association/NN
study/NN
./.
====================
The/DT
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
)/)
increased/VBD
by/IN
0.5/CD
%/NN
to/TO
5.2/CD
%/NN
when/WRB
either/CC
counted/VBN
or/CC
weighted/JJ
GRS/NN
was/VBD
added/VBN
to/TO
a/DT
prediction/NN
model/NN
consisting/VBG
of/IN
age/NN
alone/RB
(/(
AUC/NN
0.687/CD
for/IN
men/NNS
,/,
0.598/CD
for/IN
women/NNS
)/)
or/CC
age/NN
and/CC
family/NN
history/JJ
of/IN
CRC/NN
(/(
AUC/NN
0.692/CD
for/IN
men/NNS
,/,
0.603/CD
for/IN
women/NNS
)/)
for/IN
both/DT
men/NNS
and/CC
women/NNS
./.
====================
Furthermore/RB
,/,
the/DT
risk/NN
of/IN
CRC/NN
significantly/RB
increased/VBD
for/IN
individuals/NNS
with/IN
a/DT
family/NN
history/RB
of/IN
CRC/NN
in/IN
the/DT
highest/JJS
quartile/RB
of/IN
GRS/NN
when/WRB
compared/VBN
to/TO
subjects/NNS
without/IN
a/DT
family/NN
history/RB
of/IN
CRC/NN
in/IN
the/DT
lowest/JJ
quartile/RB
of/IN
GRS/NN
(/(
counted/VBN
GRS/NN
odds/NNS
ratio/RB
[/(
OR/NNP
]/)
,/,
47.9/CD
;/:
95/CD
%/NN
confidence/IN
interval/JJ
[/(
CI/NNP
]/)
,/,
4.9/CD
to/TO
471.8/CD
for/IN
men/NNS
;/:
OR/NNP
,/,
22.3/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.4/CD
to/TO
344.2/CD
for/IN
women/NNS
)/)
(/(
weighted/JJ
GRS/NN
OR/NN
,/,
35.9/CD
;/:
95/CD
%/NN
CI/NN
,/,
5.9/CD
to/TO
218.2/CD
for/IN
men/NNS
;/:
OR/NNP
,/,
18.1/CD
,/,
95/CD
%/NN
CI/NN
,/,
3.7/CD
to/TO
88.1/CD
for/IN
women/NNS
)/)
./.
====================
Our/PRP$
findings/NNS
suggest/VBP
that/IN
in/IN
Koreans/NNS
,/,
especially/RB
in/IN
Korean/JJ
men/NNS
,/,
GRS/NN
improve/VBP
the/DT
prediction/NN
of/IN
CRC/NN
when/WRB
considered/VBN
in/IN
conjunction/NN
with/IN
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
./.
====================
Colorectal/JJ
cancer/NN
(/(
CRC/NN
)/)
,/,
also/RB
called/VBN
colon/NN
cancer/NN
or/CC
large/JJ
bowel/NN
cancer/NN
,/,
includes/VBZ
cancerous/JJ
growths/NNS
in/IN
the/DT
colon/NN
,/,
rectum/NN
,/,
and/CC
appendix/JJ
[/(
1/CD
]/)
./.
====================
With/IN
655,000/CD
deaths/NNS
worldwide/NN
per/IN
year/NN
,/,
it/PRP
is/VBZ
the/DT
fourth/JJ
most/JJS
common/JJ
form/NN
of/IN
cancer/NN
in/IN
the/DT
United/JJ
States/NNS
(/(
US/NN
)/)
and/CC
the/DT
third/JJ
leading/VBG
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
in/IN
the/DT
western/NN
world/NN
[/(
1/CD
,/,
2/CD
]/)
./.
====================
In/IN
Korea/NN
,/,
CRC/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
commonly/RB
diagnosed/VBN
cancers/NNS
,/,
and/CC
its/PRP$
incidence/NN
is/VBZ
now/RB
dramatically/RB
increasing/VBG
with/IN
the/DT
westernization/NN
of/IN
lifestyles/NNS
[/(
3/CD
]/)
./.
====================
According/VBG
to/TO
statistics/NNS
for/IN
Korea/NN
,/,
the/DT
incidence/NN
of/IN
CRC/NN
was/VBD
9.8/CD
per/FW
100,000/CD
men/NNS
and/CC
10.4/CD
per/FW
100,000/CD
women/NNS
from/IN
1999-2001/CD
[/(
4/CD
]/)
./.
====================
These/DT
incidence/NN
rates/NNS
for/IN
CRC/NN
increased/VBD
to/TO
18.2/CD
per/FW
100,000/CD
men/NNS
and/CC
13.7/CD
per/FW
100,000/CD
women/NNS
in/IN
2003/CD
[/(
5/CD
]/)
./.
====================
Given/IN
the/DT
high/JJ
incidence/NN
of/IN
CRC/NN
and/CC
its/PRP$
significant/JJ
cost/JJ
to/TO
society/NN
,/,
the/DT
ability/NN
to/TO
accurately/RB
predict/VBP
the/DT
possibility/NN
of/IN
developing/VBG
the/DT
disease/NN
using/VBG
identifiable/JJ
risk/NN
factors/NNS
may/MD
help/VB
both/CC
physicians/NNS
and/CC
patients/NNS
prevent/VBP
its/PRP$
occurrence/NN
[/(
6/CD
]/)
./.
====================
Numerous/JJ
studies/NNS
have/VBP
identified/VBN
risk/NN
factors/NNS
related/JJ
to/TO
CRC/NN
,/,
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
family/NN
history/JJ
of/IN
CRC/NN
,/,
smoking/VBG
,/,
physical/JJ
activity/NN
,/,
aspirin/nonsteroidal/JJ
anti-inflammatory/JJ
drug/NN
(/(
NSAID/NN
)/)
use/VBP
,/,
vegetable/JJ
intake/JJ
,/,
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
alcohol/NN
consumption/NN
,/,
and/CC
hormone/NN
replacement/NN
therapy/NN
by/IN
women/NNS
[/(
7-10/CD
]/)
./.
====================
Recently/RB
,/,
there/EX
have/VBP
been/VBN
a/DT
number/NN
of/IN
studies/NNS
that/IN
developed/VBD
a/DT
risk/NN
score/RB
or/CC
a/DT
prediction/NN
model/NN
of/IN
certain/JJ
diseases/NNS
,/,
such/JJ
as/IN
coronary/JJ
heart/NN
disease/NN
(/(
CHD/NN
)/)
and/CC
cancers/NNS
,/,
using/VBG
these/DT
identified/VBN
risk/NN
factors/NNS
[/(
11/CD
,/,
12/CD
]/)
./.
====================
However/RB
,/,
these/DT
risk/NN
scores/NNS
or/CC
prediction/NN
models/NNS
have/VBP
excluded/VBN
genetic/JJ
risk/NN
factors/NNS
./.
====================
Genetic/JJ
polymorphisms/NNS
contributing/VBG
to/TO
certain/JJ
disease/NN
incidences/VBZ
,/,
such/JJ
as/IN
CHD/NN
,/,
could/MD
be/VB
one/CD
type/NN
of/IN
emerging/VBG
risk/NN
factor/NN
under/IN
investigation/NN
in/IN
studies/NNS
generally/RB
focused/VBN
on/IN
a/DT
priori/JJ
selected/VBN
candidate/NN
genes/NNS
[/(
13/CD
,/,
14/CD
]/)
./.
====================
Advances/NNS
in/IN
genome/NN
technologies/NNS
have/VBP
made/VBN
it/PRP
possible/JJ
to/TO
genotype/NN
and/CC
evaluate/VBP
many/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
throughout/IN
the/DT
human/JJ
genome/NN
to/TO
identify/VB
novel/JJ
disease/NN
susceptibility/NN
genes/NNS
[/(
15/CD
]/)
./.
====================
A/DT
CRC/NN
prediction/NN
model/NN
has/VBZ
been/VBN
developed/VBN
in/IN
a/DT
previous/JJ
study/NN
that/IN
estimates/VBZ
the/DT
probability/NN
of/IN
developing/VBG
CRC/NN
,/,
given/VBN
a/DT
specific/JJ
age/NN
,/,
risk/NN
factor/NN
profile/NN
,/,
and/CC
time/NN
period/NN
in/IN
white/JJ
men/NNS
and/CC
women/NNS
aged/JJ
50/CD
years/NNS
and/CC
older/JJR
[/(
16/CD
]/)
./.
====================
However/RB
,/,
genetic/JJ
polymorphisms/NNS
have/VBP
not/RB
been/VBN
included/VBN
in/IN
the/DT
study/NN
./.
====================
Another/DT
prediction/NN
model/NN
,/,
developed/VBD
among/IN
middle-aged/JJ
Japanese/JJ
men/NNS
,/,
included/VBD
conventional/JJ
risk/NN
factors/NNS
without/IN
genetic/JJ
risk/NN
factors/NNS
[/(
17/CD
]/)
./.
====================
A/DT
recent/JJ
study/NN
developed/VBD
a/DT
prediction/NN
of/IN
CHD/NN
risk/NN
,/,
aggregating/VBG
information/NN
from/IN
multiple/JJ
SNPs/NNS
into/IN
a/DT
single/JJ
genetic/JJ
risk/NN
score/RB
(/(
GRS/NN
)/)
and/CC
determined/VBN
an/DT
improvement/JJ
in/IN
the/DT
prediction/NN
of/IN
incident/JJ
CHD/NN
in/IN
the/DT
Atherosclerosis/NN
Risk/NN
in/IN
Communities/NNS
(/(
ARIC/NN
)/)
study/NN
[/(
18/CD
]/)
./.
====================
From/IN
recent/JJ
studies/NNS
,/,
several/JJ
SNPs/NNS
that/DT
may/MD
play/VB
an/DT
important/JJ
role/NN
in/IN
triggering/VBG
CRC/NN
have/VBP
been/VBN
introduced/VBN
by/IN
a/DT
genome-wide/JJ
association/NN
study/NN
(/(
GWAS/NN
)/)
among/IN
whites/VBZ
,/,
Japanese/JJ
,/,
and/CC
Chinese/JJ
but/CC
not/RB
Koreans/JJ
[/(
19-22/CD
]/)
./.
====================
Moreover/RB
,/,
prediction/NN
models/NNS
that/DT
were/VBD
developed/VBN
recently/RB
were/VBD
performed/VBN
among/IN
whites/VBZ
and/CC
the/DT
Japanese/JJ
population/NN
[/(
16/CD
,/,
17/CD
]/)
./.
====================
Previous/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
combining/VBG
multiple/JJ
loci/NNS
with/IN
modest/JJS
effects/NNS
into/IN
a/DT
global/JJ
GRS/NN
might/MD
improve/VB
the/DT
identification/NN
of/IN
persons/NNS
who/WP
are/VBP
at/IN
risk/NN
for/IN
common/JJ
complex/NN
diseases/NNS
[/(
23-25/CD
]/)
./.
====================
Therefore/RB
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
intended/VBD
to/TO
describe/VB
a/DT
GRS/NN
by/IN
aggregation/NN
of/IN
multiple/JJ
SNPs/NNS
contributing/VBG
to/TO
CRC/NN
through/IN
a/DT
GWAS/JJ
./.
====================
Furthermore/RB
,/,
we/PRP
aimed/VBD
to/TO
develop/VB
a/DT
prediction/NN
model/NN
consisting/VBG
of/IN
conventional/JJ
risk/NN
factors/NNS
as/IN
well/RB
as/IN
a/DT
genetic/JJ
risk/NN
factor/NN
,/,
such/JJ
as/IN
GRS/NN
,/,
in/IN
Koreans/NNS
in/IN
the/DT
Korean/JJ
Cancer/NN
Prevention/NN
Study-II/NN
(/(
KCPS-II/NN
)/)
./.
====================
Study/NN
population/NN
====================
The/DT
initial/JJ
study/NN
population/NN
included/VBD
200,595/CD
individuals/NNS
,/,
20-77/CD
years/NNS
of/IN
age/NN
,/,
who/WP
visited/VBD
16/CD
health/NN
promotion/NN
centers/NNS
nationwide/NN
from/IN
April/NN
2004/CD
to/TO
December/NN
2007/CD
in/IN
the/DT
KCPS-II/NN
./.
====================
Of/IN
these/DT
,/,
there/EX
were/VBD
325/CD
confirmed/VBD
cases/NNS
of/IN
CRC/NN
[/(
26/CD
]/)
,/,
but/CC
132/CD
cases/NNS
â‰¥55/CD
years/NNS
of/IN
CRC/NN
onset/NN
age/NN
were/VBD
excluded/VBN
to/TO
obtain/VB
early-onset/JJ
CRC/NN
cases/NNS
./.
====================
For/IN
controls/NNS
,/,
they/PRP
were/VBD
recruited/VBN
from/IN
the/DT
Korean/JJ
Metabolic/JJ
Syndrome/NN
Research/NN
Initiative/JJ
study/NN
,/,
a/DT
part/NN
of/IN
KCPS-II/NN
,/,
in/IN
Seoul/JJ
,/,
initiated/VBN
in/IN
December/NN
2005/CD
./.
====================
A/DT
total/JJ
of/IN
9,128/CD
individuals/NNS
were/VBD
recruited/VBN
in/IN
2006/CD
,/,
and/CC
an/DT
additional/JJ
17,569/CD
individuals/NNS
were/VBD
recruited/VBN
in/IN
2007/CD
./.
====================
Therefore/RB
,/,
the/DT
total/JJ
Seoul/JJ
cohort/NN
included/VBD
26,697/CD
volunteers/NNS
./.
====================
Volunteers/NNS
from/IN
the/DT
first/JJ
round/NN
had/VBD
routine/NN
health/NN
examinations/NNS
at/IN
the/DT
Health/NN
Promotion/NN
Center/NN
in/IN
university/NN
hospitals/NNS
between/IN
January/NN
2006/CD
and/CC
December/NN
2007/CD
./.
====================
From/IN
this/DT
total/JJ
,/,
1,004/NN
individuals/NNS
were/VBD
genotyped/VBN
using/VBG
Affymetrix/JJ
Genomewide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
Affymetrix/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
However/RB
,/,
10/CD
of/IN
1,004/NN
individuals/NNS
were/VBD
removed/VBN
because/IN
of/IN
low/JJ
genotyping/VBG
call/JJ
rates/NNS
(/(
</JJR
95/CD
%/NN
)/)
,/,
and/CC
4/CD
individuals/NNS
were/VBD
shown/VBN
to/TO
have/VB
biological/JJ
relatives/NNS
;/:
so/RB
,/,
one/CD
member/NN
of/IN
each/DT
pair/NN
was/VBD
excluded/VBN
./.
====================
Eleven/CD
and/CC
2/CD
individuals/NNS
were/VBD
also/RB
excluded/VBN
as/IN
a/DT
result/NN
of/IN
gender/NN
mismatches/NNS
[/(
27/CD
]/)
./.
====================
An/DT
additional/JJ
6/CD
cases/NNS
and/CC
1/CD
control/NN
were/VBD
excluded/VBN
due/JJ
to/TO
missing/VBG
anthropometric/JJ
measurements/NNS
(/(
height/RB
,/,
weight/NN
,/,
BMI/NNP
,/,
waist/NN
circumstance/NN
[/(
WC/NN
]/)
,/,
and/CC
blood/NN
pressure/NN
[/(
BP/NN
]/)
)/)
and/CC
self-reported/JJ
questionnaire/RB
information/NN
(/(
smoking/NN
status/NN
and/CC
alcohol/NN
consumption/NN
)/)
./.
====================
A/DT
detailed/JJ
description/NN
of/IN
the/DT
KCPS-II/NN
study/NN
design/NN
and/CC
methods/NNS
of/IN
selection/NN
of/IN
controls/NNS
in/IN
this/DT
study/NN
are/VBP
published/VBN
elsewhere/VBP
[/(
27/CD
]/)
./.
====================
Therefore/RB
,/,
a/DT
total/JJ
of/IN
1,163/CD
participants/NNS
(/(
men/NNS
,/,
687/CD
;/:
women/NNS
,/,
476/CD
)/)
were/VBD
included/VBN
in/IN
this/DT
study/NN
:/:
187/CD
cases/NNS
(/(
men/NNS
,/,
133/CD
;/:
women/NNS
,/,
54/CD
)/)
and/CC
976/CD
controls/NNS
(/(
men/NNS
,/,
554/CD
;/:
women/NNS
,/,
422/CD
)/)
./.
====================
A/DT
written/JJ
consent/JJ
form/VBP
was/VBD
signed/VBN
by/IN
all/DT
study/NN
participants/NNS
,/,
and/CC
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Yonsei/NNS
University/NN
approved/JJ
the/DT
study/NN
protocol/NN
./.
====================
Genotyping/VBG
====================
DNA/NN
samples/NNS
were/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
of/IN
participants/NNS
and/CC
genotyped/VBD
using/VBG
Affymetrix/JJ
Genomewide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
Affymetrix/JJ
Inc./NNP
)/)
at/IN
DNA/NN
Link/NN
Inc./NNP
(/(
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Internal/JJ
quality/NN
control/NN
(/(
QC/NN
)/)
measures/VBZ
were/VBD
employed/VBN
to/TO
ensure/VB
accuracy/NN
of/IN
the/DT
data/NNS
./.
====================
The/DT
QC/NN
call/JJ
rate/NN
(/(
dynamic/JJ
model/NN
algorithm/NN
)/)
was/VBD
â‰¥95/CD
%/NN
,/,
and/CC
heterozygosity/NN
of/IN
X/NN
chromosome/NN
markers/NNS
identified/VBD
the/DT
gender/NN
for/IN
each/DT
sample/NN
./.
====================
Genotype/NN
calling/JJ
was/VBD
performed/VBN
by/IN
Birdseed/JJ
(/(
v2/NN
)/)
algorithm/NN
./.
====================
Chromosome/NN
Y/NN
was/VBD
not/RB
analyzed/VBN
./.
====================
A/DT
total/JJ
of/IN
1,163/CD
individuals/NNS
were/VBD
genotyped/VBN
via/IN
this/DT
platform/NN
in/IN
the/DT
analysis/NN
./.
====================
PLINK/NN
(/(
v1.07/CD
)/)
was/VBD
used/VBN
to/TO
estimate/VB
identity/NN
by/IN
state/NN
(/(
IBS/NN
)/)
over/IN
all/DT
SNPs/NNS
[/(
28/CD
]/)
./.
====================
A/DT
default/NN
set/NN
of/IN
426,019/CD
SNPs/NNS
was/VBD
used/VBN
for/IN
further/JJ
analysis/NN
,/,
as/IN
recommended/VBN
by/IN
Affymetrix/JJ
./.
====================
In/IN
the/DT
quality/NN
assurance/NN
screening/NN
,/,
we/PRP
flagged/VBD
SNPs/NNS
with/IN
genotype/NN
call/JJ
rates/NNS
</JJR
95/CD
%/NN
,/,
minor/JJ
allele/NN
frequencies/NNS
</JJR
0.01/CD
,/,
and/CC
SNPs/NNS
showing/VBG
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NN
)/)
at/IN
p/NN
</JJR
0.0000001/CD
./.
====================
The/DT
final/JJ
set/NN
of/IN
acceptable/JJ
markers/NNS
included/VBD
312,506/CD
autosomal/JJ
SNPs/NNS
./.
====================
Accuracy/NN
of/IN
the/DT
genotyping/VBG
was/VBD
calculated/VBN
by/IN
Bayesian/JJ
robust/JJ
linear/JJ
modeling/VBG
using/VBG
the/DT
Mahalanobis/NN
distance/NN
(/(
BRLMN/NN
)/)
algorithm/NN
[/(
29/CD
]/)
./.
====================
Chemistry/NN
and/CC
anthropometric/JJ
measurements/NNS
====================
Serum/NN
,/,
separated/VBN
from/IN
peripheral/JJ
venous/JJ
blood/NN
,/,
was/VBD
obtained/VBN
from/IN
each/DT
participant/NN
after/IN
a/DT
12-h/JJ
fast/JJ
and/CC
then/RB
stored/VBD
at/IN
-70â„ƒ/CD
until/IN
analyzed/VBD
./.
====================
For/IN
anthropometric/JJ
measurements/NNS
,/,
WC/NN
was/VBD
measured/VBN
on/IN
exposed/VBN
waists/NNS
midway/NN
between/IN
the/DT
lower/JJR
rib/NN
and/CC
the/DT
iliac/JJ
crest/VBP
using/VBG
a/DT
measuring/VBG
tape/NN
./.
====================
For/IN
difficult/JJ
cases/NNS
,/,
WC/NN
was/VBD
measured/VBN
at/IN
3/CD
cm/NN
above/JJ
the/DT
navel/JJ
./.
====================
Weight/PRP
and/CC
height/NN
were/VBD
measured/VBN
while/IN
participants/NNS
were/VBD
wearing/JJ
light/NN
clothing/VBG
./.
====================
BMI/NN
was/VBD
calculated/VBN
as/IN
weight/NN
(/(
kg/NN
)/)
divided/VBN
by/IN
height/NN
squared/VBD
(/(
m2/NN
)/)
./.
====================
Both/DT
systolic/JJ
and/CC
diastolic/JJ
BP/NN
was/VBD
measured/VBN
after/IN
a/DT
15-min/NN
rest/VBP
./.
====================
In/IN
addition/NN
,/,
each/DT
participant/JJ
was/VBD
interviewed/VBN
using/VBG
a/DT
structured/JJ
questionnaire/RB
to/TO
collect/VB
information/NN
on/IN
smoking/NN
and/CC
alcohol/NN
consumption/NN
as/IN
well/RB
as/IN
demographic/JJ
characteristics/NNS
,/,
such/JJ
as/IN
age/NN
,/,
gender/RB
,/,
and/CC
family/NN
and/CC
past/NN
history/JJ
of/IN
clinical/JJ
diseases/NNS
./.
====================
Cigarette/NN
smoking/NN
was/VBD
classified/VBN
into/IN
never/RB
smokers/NNS
,/,
ex-smokers/VBZ
,/,
and/CC
current/JJ
smokers/NNS
./.
====================
Alcohol/NN
consumption/NN
was/VBD
divided/VBN
into/IN
nondrinkers/NNS
and/CC
current/JJ
drinkers/NNS
./.
====================
Regular/JJ
physical/JJ
activity/NN
was/VBD
tracked/VBN
as/IN
either/CC
``/CD
yes/NNS
''/CD
or/CC
``/NN
no/DT
''/JJ
./.
====================
SNP/NN
selection/NN
and/CC
GRS/NN
calculation/NN
====================
In/IN
the/DT
association/NN
of/IN
SNPs/NNS
with/IN
CRC/NN
,/,
the/DT
SNPs/NNS
with/IN
p/NN
</JJR
10-5/CD
in/IN
Korean/JJ
men/NNS
were/VBD
:/:
rs17391002/RB
(/(
CXCL12/NN
)/)
,/,
rs9549448/RB
(/(
SOX1/NN
)/)
,/,
rs254833/RB
(/(
MYO10/NNP
)/)
,/,
rs2553614/RB
(/(
TMEM71/NNP
)/)
,/,
rs13153032/RB
(/(
NSUN2/NNP
)/)
,/,
rs2288073/RB
(/(
FLJ30851/CD
)/)
,/,
rs9604214/RB
(/(
SOX1/NN
)/)
,/,
rs9865670/RB
(/(
OPA1/NN
)/)
,/,
rs17186320/RB
(/(
KIAA1009/CD
)/)
,/,
rs1509497/RB
(/(
RFX8/NNP
)/)
,/,
rs235428/RB
(/(
PHF20L1/NN
)/)
,/,
rs9845920/RB
(/(
OPA1/NN
)/)
,/,
rs9846212/RB
(/(
OPA1/NN
)/)
,/,
rs6763744/RB
(/(
OPA1/NN
)/)
,/,
rs4128317/RB
(/(
ALK/NNP
)/)
,/,
rs7646304/RB
(/(
OPA1/NN
)/)
,/,
rs17047306/RB
(/(
SPATA17/NNP
)/)
,/,
rs1490338/RB
(/(
SPATA17/NNP
)/)
,/,
rs902351/RB
(/(
SPATA17/NNP
)/)
,/,
and/CC
rs2543662/RB
(/(
ITSN2/NNP
)/)
(/(
Supplementary/NNP
Table/JJ
1/LS
)/)
./.
====================
The/DT
SNPs/NNS
with/IN
p/NN
</JJR
10-5/CD
in/IN
Korean/JJ
women/NNS
in/IN
the/DT
association/NN
between/IN
SNPs/NNS
and/CC
CRC/NN
were/VBD
:/:
rs10083736/RB
(/(
GOT2/NNP
)/)
,/,
rs16987827/RB
(/(
DHX35/NNP
)/)
,/,
rs8046516/RB
(/(
GOT2/NNP
)/)
,/,
rs9926182/RB
(/(
GOT2/NNP
)/)
,/,
rs17523778/RB
(/(
FAM174B/NN
)/)
,/,
rs4974411/RB
(/(
TPRA1/NN
)/)
,/,
rs1834902/RB
(/(
H2AFY/NNP
)/)
,/,
rs16895308/RB
(/(
MAST4/NNP
)/)
,/,
rs8032832/RB
(/(
FAM174B/NN
)/)
,/,
rs6901560/RB
(/(
PD6/NN
)/)
,/,
rs11025480/RB
(/(
PRMT3/NN
)/)
,/,
rs3814110/RB
(/(
BNC2/NNP
)/)
,/,
rs16895307/RB
(/(
MAST4/NNP
)/)
,/,
rs7089063/RB
(/(
MARCH8/NNP
)/)
,/,
rs16893688/RB
(/(
IBTK/NNP
)/)
,/,
rs6861487/RB
(/(
MAST4/NNP
)/)
,/,
rs9613463/RB
(/(
MN1/NNP
)/)
,/,
rs11242237/RB
(/(
H2AFY/NNP
)/)
,/,
rs11150094/RB
(/(
WWOX/NNP
)/)
,/,
and/CC
rs9625253/RB
(/(
MN1/NNP
)/)
(/(
Supplementary/NNP
Table/JJ
2/CD
)/)
./.
====================
Each/DT
SNP/NN
in/IN
this/DT
study/NN
was/VBD
assumed/VBN
to/TO
be/VB
associated/VBN
with/IN
risk/NN
according/VBG
to/TO
an/DT
additive/JJ
genetic/JJ
model/NN
,/,
which/WDT
performs/VBZ
well/RB
,/,
even/RB
when/WRB
the/DT
true/JJ
genetic/JJ
model/NN
may/MD
not/RB
be/VB
known/VBN
or/CC
may/MD
be/VB
incorrectly/RB
specified/VBN
[/(
30/CD
]/)
./.
====================
A/DT
GRS/NN
was/VBD
calculated/VBN
on/IN
the/DT
basis/NN
of/IN
reproducible/JJ
tagging/VBG
of/IN
SNP-associated/JJ
loci/NNS
reaching/VBG
genomewide/NN
levels/NNS
of/IN
significance/NN
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
GRS/NN
was/VBD
calculated/VBN
with/IN
the/DT
3/CD
SNPs/NNS
in/IN
Korean/JJ
men/NNS
and/CC
5/CD
SNPs/NNS
in/IN
Korean/JJ
women/NNS
showing/VBG
the/DT
strongest/JJS
association/NN
with/IN
CRC/NN
(/(
p/NN
</JJR
10-6/CD
)/)
./.
====================
The/DT
GRS/NN
was/VBD
created/VBN
by/IN
two/CD
methods/NNS
:/:
a/DT
simple/JJ
count/NN
method/NN
(/(
count/NN
GRS/NN
)/)
and/CC
a/DT
weighted/JJ
method/NN
(/(
weighted/JJ
GRS/NN
)/)
[/(
31/CD
,/,
32/CD
]/)
./.
====================
Both/DT
methods/NNS
anticipated/JJ
each/DT
SNP/NN
to/TO
be/VB
independently/RB
associated/VBN
with/IN
risk/NN
./.
====================
We/PRP
assumed/VBD
an/DT
additive/JJ
genetic/JJ
model/NN
for/IN
each/DT
SNP/NN
,/,
applying/VBG
a/DT
linear/JJ
weighting/VBG
of/IN
0/CD
,/,
1/CD
,/,
or/CC
2/CD
to/TO
genotypes/NNS
containing/VBG
0/CD
,/,
1/CD
,/,
or/CC
2/CD
risk/NN
alleles/NNS
,/,
respectively/RB
./.
====================
This/DT
model/NN
is/VBZ
known/VBN
to/TO
perform/VB
well/RB
,/,
even/RB
when/WRB
the/DT
true/JJ
genetic/JJ
model/NN
is/VBZ
unknown/JJ
or/CC
wrongly/RB
specified/VBN
[/(
30/CD
]/)
./.
====================
The/DT
count/NN
model/NN
assumes/VBZ
that/DT
each/DT
SNP/NN
in/IN
the/DT
panel/NN
contributes/VBZ
equally/RB
to/TO
the/DT
risk/NN
for/IN
CRC/NN
and/CC
was/VBD
calculated/VBN
by/IN
summing/VBG
the/DT
values/NNS
for/IN
each/DT
of/IN
the/DT
SNPs/NNS
./.
====================
The/DT
weighted/JJ
GRS/NN
was/VBD
calculated/VBN
by/IN
multiplying/VBG
each/DT
beta-coefficient/JJ
by/IN
the/DT
number/NN
of/IN
corresponding/JJ
risk/NN
alleles/NNS
(/(
0/CD
,/,
1/CD
,/,
2/CD
)/)
./.
====================
Outcome/DT
classification/NN
====================
The/DT
principle/JJ
outcome/NN
variables/NNS
were/VBD
prevalence/RB
(/(
n/NN
=/JJ
165/CD
)/)
and/CC
incidence/NN
rates/NNS
(/(
n/NN
=/JJ
22/CD
)/)
,/,
based/VBN
on/IN
national/JJ
cancer/NN
registry/NN
and/CC
hospitalization/NN
records/VBZ
./.
====================
Although/IN
Korea/NN
has/VBZ
a/DT
national/JJ
cancer/NN
registry/NN
,/,
reporting/VBG
was/VBD
not/RB
complete/JJ
during/IN
the/DT
time/NN
of/IN
follow-up/JJ
,/,
and/CC
consequently/RB
,/,
hospital/JJ
admission/NN
files/NNS
were/VBD
used/VBN
to/TO
identify/VB
first/JJ
admission/NN
events/NNS
for/IN
CRC/NN
./.
====================
An/DT
incident/JJ
of/IN
CRC/NN
was/VBD
coded/VBN
as/IN
occurring/VBG
,/,
based/VBN
on/IN
either/CC
a/DT
positive/JJ
report/NN
from/IN
the/DT
national/JJ
cancer/NN
registry/NN
or/CC
upon/IN
hospital/JJ
admission/NN
for/IN
a/DT
cancer/NN
diagnosis/NN
[/(
33/CD
]/)
./.
====================
According/VBG
to/TO
the/DT
International/JJ
Classification/NN
of/IN
Diseases/NNS
,/,
Tenth/NNP
Revision/NN
(/(
ICD-10/NN
)/)
,/,
CRC/NN
was/VBD
coded/VBN
as/IN
C18-C20/NN
[/(
34/CD
]/)
./.
====================
Statistical/JJ
analysis/NN
====================
All/DT
analyses/NNS
were/VBD
conducted/VBN
using/VBG
PLINK/NN
version/NN
1.06/CD
(/(
Free/JJ
Software/JJ
Foundation/NN
,/,
Inc./NNP
,/,
Boston/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
and/CC
SAS/NN
statistical/JJ
software/RB
version/NN
9.0/CD
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NNP
)/)
./.
====================
All/DT
statistical/JJ
tests/NNS
were/VBD
two-sided/VBN
,/,
and/CC
statistical/JJ
significance/NN
was/VBD
determined/VBN
as/IN
p/NN
</JJR
0.05/CD
./.
====================
To/TO
evaluate/VB
general/JJ
characteristics/NNS
of/IN
the/DT
study/NN
population/NN
,/,
means/NNS
and/CC
standard/JJ
deviations/NNS
(/(
SD/NN
)/)
were/VBD
calculated/VBN
,/,
and/CC
frequency/NN
of/IN
cigarette/JJ
smoking/NN
,/,
alcohol/NN
consumption/NN
,/,
and/CC
physical/JJ
activity/NN
was/VBD
determined/VBN
./.
====================
Paired/JJ
t-tests/NNS
were/VBD
performed/VBN
to/TO
indicate/VB
the/DT
differences/NNS
between/IN
case/NN
participants/NNS
and/CC
control/NN
participants/NNS
for/IN
both/DT
men/NNS
and/CC
women/NNS
./.
====================
A/DT
X2/NN
goodness-of-fit/NN
test/NN
was/VBD
used/VBN
to/TO
assess/VB
whether/IN
SNPs/NNS
were/VBD
in/IN
HWE/NN
and/CC
to/TO
determine/VB
differences/NNS
in/IN
genotype/NN
frequencies/NNS
between/IN
CRC/NN
cases/NNS
and/CC
controls/VBZ
./.
====================
The/DT
GRS/NN
was/VBD
categorized/VBN
into/IN
quartiles/NNS
./.
====================
The/DT
CRC/NN
risk/NN
associated/VBN
with/IN
genotype/NN
was/VBD
estimated/VBN
as/IN
s/NNS
ORs/NNS
and/CC
95/CD
%/NN
confidence/NN
interval/JJ
(/(
CI/NN
)/)
,/,
computed/VBD
using/VBG
logistic/JJ
regression/NN
with/IN
an/DT
additive/JJ
genetic/JJ
model/NN
./.
====================
We/PRP
also/RB
used/VBN
receiver/RB
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
curve/VBP
analysis/NN
and/CC
calculated/VBN
the/DT
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
;/:
also/RB
known/VBN
as/IN
the/DT
C/NN
statistic/JJ
)/)
to/TO
evaluate/VB
the/DT
discrimination/NN
power/JJR
of/IN
the/DT
model/NN
./.
====================
In/IN
addition/NN
,/,
internal/JJ
validity/NN
of/IN
each/DT
model/NN
was/VBD
checked/VBN
using/VBG
bootstrap/JJ
[/(
35/CD
]/)
,/,
while/IN
10-fold/JJ
crossvalidation/NN
was/VBD
used/VBN
for/IN
the/DT
external/JJ
validity/NN
of/IN
each/DT
model/NN
(/(
Supplementary/JJ
Tables/NNS
3/CD
and/CC
4/CD
)/)
[/(
36/CD
]/)
./.
====================
Our/PRP$
analysis/NN
included/VBD
687/CD
men/NNS
(/(
cases/NNS
,/,
133/CD
;/:
controls/VBZ
,/,
554/CD
)/)
and/CC
476/CD
women/NNS
(/(
cases/NNS
,/,
54/CD
;/:
controls/VBZ
,/,
422/CD
)/)
,/,
20-77/CD
years/NNS
of/IN
age/NN
./.
====================
The/DT
number/NN
of/IN
prevalent/JJ
cases/NNS
of/IN
CRC/NN
identified/VBN
was/VBD
166/CD
./.
====================
An/DT
additional/JJ
22/CD
incident/JJ
cases/NNS
of/IN
CRC/NN
occurred/VBD
during/IN
follow-up/JJ
./.
====================
Table/JJ
1/CD
details/VBZ
the/DT
general/JJ
characteristics/NNS
of/IN
case/NN
participants/NNS
and/CC
control/NN
participants/NNS
at/IN
baseline/NN
./.
====================
The/DT
mean/JJ
age/NN
(/(
SD/NN
)/)
was/VBD
42.9/CD
(/(
Â±/CD
8.7/CD
)/)
years/NNS
for/IN
the/DT
study/NN
population-43.5/NN
(/(
Â±/CD
8.9/CD
)/)
for/IN
men/NNS
and/CC
42.0/CD
(/(
Â±/CD
8.4/CD
)/)
for/IN
women/NNS
,/,
respectively/RB
./.
====================
No/DT
significant/JJ
differences/NNS
were/VBD
observed/VBN
in/IN
BMI/NN
,/,
WC/NNP
,/,
systolic/JJ
BP/NN
,/,
or/CC
diastolic/JJ
BP/NN
among/IN
case/NN
participants/NNS
and/CC
control/JJ
participants/NNS
for/IN
both/DT
men/NNS
and/CC
women/NNS
(/(
p/NN
>/JJR
0.05/CD
)/)
;/:
however/RB
,/,
case/NN
participants/NNS
were/VBD
older/RBR
and/CC
had/VBD
a/DT
family/NN
history/JJ
of/IN
CRC/NN
more/RBR
than/IN
control/JJ
participants/NNS
in/IN
both/DT
men/NNS
and/CC
women/NNS
(/(
p/NN
</JJR
0.001/CD
)/)
./.
====================
Table/JJ
2/CD
indicates/VBZ
the/DT
area/NN
under/IN
the/DT
ROC/NN
curves/NNS
for/IN
models/NNS
that/DT
included/VBD
both/CC
conventional/JJ
risk/NN
factors/NNS
and/CC
a/DT
genetic/JJ
risk/NN
factor/NN
,/,
GRS/NN
,/,
compared/VBN
with/IN
the/DT
AUC/NN
for/IN
the/DT
model/NN
that/DT
included/VBD
only/RB
conventional/JJ
risk/NN
factors/NNS
./.
====================
In/IN
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
,/,
we/PRP
included/VBD
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
as/IN
conventional/JJ
risk/NN
factors/NNS
and/CC
counted/VBN
GRS/NN
or/CC
weighted/JJ
GRS/NN
as/IN
genetic/JJ
risk/NN
factors/NNS
./.
====================
For/IN
both/CC
men/NNS
and/CC
women/NNS
,/,
including/VBG
the/DT
GRS/NN
in/IN
the/DT
model/NN
increased/VBD
the/DT
AUC/NN
over/IN
that/DT
observed/VBN
when/WRB
the/DT
AUC/NN
was/VBD
based/VBN
on/IN
only/RB
age/NN
or/CC
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
./.
====================
For/IN
men/NNS
,/,
the/DT
AUC/NN
(/(
95/CD
%/NN
CI/NN
)/)
was/VBD
0.729/CD
(/(
range/NN
,/,
0.682/CD
to/TO
0.767/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
plus/CC
counted/JJ
GRS/NN
(/(
p/NN
</JJR
0.001/CD
)/)
and/CC
0.719/CD
(/(
range/NN
,/,
0.677/CD
to/TO
0.761/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
plus/CC
weighted/JJ
GRS/NN
(/(
p/NN
</JJR
0.001/CD
)/)
./.
====================
The/DT
AUC/NN
(/(
95/CD
%/NN
CI/NN
)/)
was/VBD
0.692/CD
(/(
range/NN
,/,
0.647/CD
to/TO
0.732/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
alone/RB
./.
====================
The/DT
increase/NN
in/IN
the/DT
AUC/NN
for/IN
the/DT
model/NN
with/IN
counted/VBN
GRS/NN
was/VBD
0.042/CD
and/CC
0.032/CD
for/IN
the/DT
model/NN
with/IN
weighted/JJ
GRS/NN
./.
====================
For/IN
women/NNS
,/,
the/DT
AUC/NN
(/(
95/CD
%/NN
CI/NN
)/)
was/VBD
0.650/CD
(/(
range/NN
,/,
0.615/CD
to/TO
0.680/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
plus/CC
counted/JJ
GRS/NN
(/(
p/NN
</JJR
0.001/CD
)/)
and/CC
0.646/CD
(/(
range/NN
,/,
0.612/CD
to/TO
0.674/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
plus/CC
weighted/JJ
GRS/NN
(/(
p/NN
</JJR
0.001/CD
)/)
./.
====================
The/DT
AUC/NN
(/(
95/CD
%/NN
CI/NN
)/)
was/VBD
0.603/CD
(/(
range/NN
,/,
0.569/CD
to/TO
0.637/CD
)/)
for/IN
conventional/JJ
risk/NN
factors/NNS
alone/RB
./.
====================
The/DT
increase/NN
in/IN
the/DT
AUC/NN
for/IN
the/DT
model/NN
with/IN
counted/VBN
GRS/NN
was/VBD
0.052/CD
and/CC
0.048/CD
for/IN
the/DT
model/NN
with/IN
weighted/JJ
GRS/NN
./.
====================
We/PRP
further/RB
examined/VBN
the/DT
association/NN
between/IN
GRS/NN
and/CC
CRC/NN
risk/NN
for/IN
both/DT
men/NNS
and/CC
women/NNS
in/IN
the/DT
KCPS-II/NN
,/,
with/IN
stratification/NN
by/IN
family/NN
history/NN
of/IN
CRC/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
interaction/NN
between/IN
counted/VBN
or/CC
weighted/JJ
GRS/NN
and/CC
family/NN
history/JJ
of/IN
CRC/NN
was/VBD
significant/JJ
in/IN
men/NNS
,/,
indicating/VBG
a/DT
stronger/JJR
genetic/JJ
effect/NN
among/IN
participants/NNS
with/IN
a/DT
positive/JJ
family/NN
history/JJ
of/IN
CRC/NN
than/IN
in/IN
those/DT
without/IN
it/PRP
(/(
p/NN
for/IN
interaction/NN
</JJR
0.05/CD
)/)
(/(
ROC/NN
,/,
0.834/CD
for/IN
counted/JJ
GRS/NN
;/:
ROC/NN
,/,
0.822/CD
for/IN
weighted/JJ
GRS/NN
)/)
./.
====================
Women/RB
with/IN
a/DT
positive/JJ
family/NN
history/JJ
of/IN
CRC/NN
in/IN
the/DT
highest/JJS
quartile/RB
of/IN
weighted/JJ
GRS/NN
had/VBD
an/DT
OR/NN
of/IN
22.3/CD
(/(
95/CD
%/NN
CI/NN
,/,
1.4/CD
to/TO
344.2/CD
)/)
and/CC
18.1/CD
(/(
95/CD
%/NN
CI/NN
,/,
3.7/CD
to/TO
88.1/CD
)/)
compared/VBN
to/TO
those/DT
without/IN
a/DT
family/NN
history/JJ
of/IN
CRC/NN
and/CC
counted/VBN
or/CC
weighted/JJ
GRS/NN
in/IN
the/DT
lowest/JJ
quartile/RB
,/,
respectively/RB
(/(
ROC/NN
=/JJ
0.826/CD
for/IN
counted/JJ
GRS/NN
;/:
ROC/NN
=/JJ
0.818/CD
for/IN
weighted/JJ
GRS/NN
)/)
./.
====================
However/RB
,/,
they/PRP
were/VBD
not/RB
statistically/RB
significant/JJ
(/(
p/NN
for/IN
interaction/NN
>/JJR
0.05/CD
)/)
./.
====================
In/IN
addition/NN
,/,
smoking/NN
,/,
alcohol/NN
consumption/NN
,/,
BMI/NN
,/,
and/CC
WC/NN
did/VBD
not/RB
interact/VB
significantly/RB
with/IN
GRS/NN
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
This/DT
study/NN
evaluated/VBD
the/DT
ability/NN
of/IN
the/DT
GRS/NN
,/,
which/WDT
aggregates/VBZ
information/NN
from/IN
multiple/JJ
genetic/JJ
variants/NNS
,/,
to/TO
improve/VB
the/DT
prediction/NN
of/IN
CRC/NN
risk/NN
beyond/CC
the/DT
prediction/NN
risk/NN
afforded/VBD
using/VBG
conventional/JJ
risk/NN
factors/NNS
./.
====================
For/IN
both/DT
men/NNS
and/CC
women/NNS
,/,
inclusion/NN
of/IN
counted/JJ
GRS/NN
or/CC
weighted/JJ
GRS/NN
increased/VBD
the/DT
AUC/NN
by/IN
0.5/CD
%/NN
to/TO
4.2/CD
%/NN
beyond/IN
the/DT
AUC/NN
provided/VBD
by/IN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
./.
====================
Men/RB
with/IN
a/DT
positive/JJ
family/NN
history/NN
of/IN
CRC/NN
and/CC
GRS/NN
in/IN
the/DT
highest/JJS
quartile/RB
were/VBD
determined/VBN
to/TO
have/VB
a/DT
statistically/RB
significant/JJ
increased/VBD
risk/NN
of/IN
CRC/NN
than/IN
those/DT
without/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
and/CC
GRS/NN
in/IN
the/DT
lowest/JJS
quartile/RB
./.
====================
However/RB
,/,
women/NNS
with/IN
a/DT
positive/JJ
history/JJ
of/IN
CRC/NN
and/CC
GRS/NN
in/IN
the/DT
highest/JJS
quartile/RB
were/VBD
determined/VBN
to/TO
have/VB
an/DT
increased/VBN
risk/NN
of/IN
CRC/NN
than/IN
those/DT
without/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
and/CC
GRS/NN
in/IN
the/DT
lowest/JJS
quartile/RB
,/,
but/CC
this/DT
result/NN
was/VBD
not/RB
statistically/RB
significant/JJ
./.
====================
CRC/NN
is/VBZ
a/DT
multifactorial/JJ
disease/NN
involving/VBG
a/DT
variety/NN
of/IN
elements/NNS
,/,
leading/VBG
to/TO
the/DT
development/NN
of/IN
clinical/JJ
manifestations/NNS
[/(
37/CD
]/)
./.
====================
This/DT
recognition/NN
had/VBD
led/VBD
to/TO
the/DT
development/NN
of/IN
risk/NN
assessment/NN
tools/NNS
that/DT
attempt/VBP
to/TO
synthesize/VB
the/DT
values/NNS
of/IN
numerous/JJ
variables/NNS
into/IN
a/DT
single/JJ
statement/JJ
regarding/VBG
the/DT
risk/NN
of/IN
developing/VBG
cancer/NN
[/(
38/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
20/CD
SNPs/NNS
were/VBD
respectively/RB
genotyped/VBD
in/IN
Korean/JJ
men/NNS
and/CC
women/NNS
./.
====================
Among/IN
these/DT
SNPs/NNS
,/,
3/CD
SNPs/NNS
in/IN
Korean/JJ
men/NNS
and/CC
5/CD
SNPs/NNS
in/IN
Korean/JJ
women/NNS
showing/VBG
the/DT
strongest/JJS
association/NN
with/IN
CRC/NN
were/VBD
used/VBN
for/IN
the/DT
calculation/NN
of/IN
GRS/NN
./.
====================
The/DT
GRS/NN
was/VBD
calculated/VBN
using/VBG
a/DT
linear/JJ
weighting/VBG
of/IN
0/CD
,/,
1/CD
,/,
or/CC
2/CD
for/IN
genotypes/NNS
containing/VBG
0/CD
,/,
1/CD
,/,
or/CC
2/CD
risk/NN
alleles/NNS
,/,
respectively/RB
./.
====================
The/DT
weighted/JJ
GRS/NN
was/VBD
computed/VBN
by/IN
multiplying/VBG
each/DT
beta-coefficient/JJ
by/IN
the/DT
number/NN
of/IN
corresponding/JJ
risk/NN
alleles/NNS
./.
====================
However/RB
,/,
when/WRB
multiplying/JJ
each/DT
beta-coefficient/JJ
by/IN
the/DT
number/NN
of/IN
corresponding/JJ
risk/NN
alleles/NNS
,/,
negative/JJ
values/NNS
of/IN
beta-coefficients/NNS
may/MD
be/VB
obtained/VBN
in/IN
some/DT
genotypes/NNS
of/IN
the/DT
SNPs/NNS
./.
====================
Therefore/RB
,/,
it/PRP
may/MD
affect/VB
the/DT
OR/NN
values/NNS
for/IN
CRC/NN
when/WRB
compared/VBN
to/TO
the/DT
OR/NN
values/NNS
for/IN
CRC/NN
determined/VBN
using/VBG
counted/JJ
GRS/NN
./.
====================
Still/RB
,/,
the/DT
calculation/NN
results/NNS
of/IN
both/DT
counted/VBN
GRS/NN
and/CC
weighted/JJ
GRS/NN
were/VBD
similar/JJ
to/TO
each/DT
other/JJ
./.
====================
Cornelis/NN
et/FW
al/JJ
./.
====================
[/(
31/CD
]/)
and/CC
Ripatti/NN
et/FW
al/JJ
./.
====================
[/(
32/CD
]/)
used/VBN
methods/NNS
similar/JJ
to/TO
the/DT
GRS/NN
created/VBD
for/IN
our/PRP$
study/NN
./.
====================
Several/JJ
other/JJ
studies/NNS
have/VBP
reported/VBN
different/JJ
ways/NNS
of/IN
calculating/JJ
risk/NN
scores/NNS
for/IN
the/DT
prediction/NN
of/IN
diseases/NNS
[/(
39-41/CD
]/)
./.
====================
Horne/NN
et/FW
al/JJ
./.
====================
[/(
39/CD
]/)
introduced/VBD
a/DT
regression/NN
method/NN
for/IN
calculating/JJ
risk/NN
scores/NNS
that/DT
incorporated/VBN
3/CD
genetic/JJ
polymorphisms/NNS
and/CC
other/JJ
risk/NN
factors/NNS
and/CC
found/VBD
that/IN
the/DT
frequency/NN
of/IN
coronary/JJ
heart/NN
disease/NN
was/VBD
different/JJ
at/IN
different/JJ
regression/NN
score/RB
levels/NNS
./.
====================
Ortlepp/JJ
et/FW
al/JJ
./.
====================
[/(
40/CD
]/)
concluded/VBD
that/IN
multiple/JJ
SNPs/NNS
are/VBP
better/RBR
than/IN
single/JJ
SNPs/NNS
and/CC
that/IN
as/IN
many/JJ
as/IN
200/CD
SNPs/NNS
may/MD
be/VB
necessary/JJ
for/IN
``/NN
reasonable/JJ
''/CD
genetic/JJ
discrimination/NN
./.
====================
Aston/NN
et/FW
al/JJ
./.
====================
[/(
41/CD
]/)
suggested/VBD
that/IN
a/DT
score/RB
based/VBN
on/IN
90/CD
SNPs/NNS
in/IN
78/CD
genes/NNS
can/MD
predict/VB
the/DT
risk/NN
of/IN
breast/NN
cancer/NN
,/,
but/CC
the/DT
identity/NN
of/IN
the/DT
SNPs/NNS
and/CC
the/DT
algorithm/NN
for/IN
calculating/JJ
the/DT
score/NN
remain/VBP
proprietary/JJ
./.
====================
An/DT
alternative/JJ
way/NN
to/TO
calculate/JJ
GRS/NN
using/VBG
machine/JJ
approaches/NNS
,/,
such/JJ
as/IN
support/VBP
vector/NN
machines/NNS
(/(
SVMs/NNS
)/)
,/,
could/MD
be/VB
introduced/VBN
,/,
as/IN
SVMs/NNS
have/VBP
already/RB
been/VBN
used/VBN
to/TO
deal/JJ
with/IN
many/JJ
biological/JJ
problems/NNS
,/,
such/JJ
as/IN
DNA/NN
expression/NN
profiles/NNS
[/(
42/CD
]/)
./.
====================
Still/RB
,/,
further/RBR
studies/NNS
are/VBP
needed/VBN
to/TO
use/VB
machine/NN
learning/VBG
approaches/NNS
,/,
such/JJ
as/IN
SVMs/NNS
,/,
for/IN
the/DT
calculation/NN
of/IN
GRS/NN
./.
====================
To/TO
our/PRP$
knowledge/NN
,/,
there/EX
have/VBP
been/VBN
no/DT
studies/NNS
evaluating/VBG
a/DT
GRS/NN
using/VBG
SNPs/NNS
contributing/VBG
to/TO
CRC/NN
for/IN
the/DT
prediction/NN
of/IN
the/DT
disease/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
The/DT
present/JJ
study/NN
evaluated/VBD
a/DT
prediction/NN
model/NN
using/VBG
counted/JJ
GRS/NN
or/CC
weighted/JJ
GRS/NN
together/RB
with/IN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
among/IN
Koreans/NNS
./.
====================
The/DT
risk/NN
of/IN
CRC/NN
is/VBZ
said/VBN
to/TO
increase/VB
in/IN
individuals/NNS
with/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
,/,
in/IN
particular/JJ
those/DT
>/JJR
50/CD
years/NNS
of/IN
age/NN
[/(
43/CD
,/,
44/CD
]/)
./.
====================
From/IN
a/DT
recent/JJ
study/NN
,/,
a/DT
CRC/NN
prediction/NN
model/NN
was/VBD
developed/VBN
with/IN
known/VBN
major/JJ
risk/NN
factors/NNS
of/IN
age/NN
,/,
BMI/NN
,/,
alcohol/NN
consumption/NN
,/,
smoking/VBG
status/NN
,/,
and/CC
physical/JJ
activity/NN
level/NN
for/IN
middle-aged/JJ
Japanese/JJ
men/NNS
[/(
17/CD
]/)
./.
====================
Another/DT
recent/JJ
study/NN
on/IN
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
included/VBD
an/DT
individual/JJ
's/POS
age/NN
,/,
sex/NN
,/,
history/JJ
of/IN
CRC/NN
,/,
sigmoidoscopy/colonoscopy/NN
,/,
polyps/RB
,/,
family/NN
history/NN
of/IN
CRC/NN
,/,
smoking/VBG
,/,
physical/JJ
activity/NN
,/,
aspirin/NSAID/NN
use/NN
,/,
vegetable/JJ
intake/JJ
,/,
BMI/NNP
,/,
and/CC
hormone/NN
replacement/NN
in/IN
women/NNS
[/(
16/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
was/VBD
comprised/VBN
of/IN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
,/,
together/RB
with/IN
the/DT
GRS/NN
./.
====================
As/IN
determined/VBN
,/,
inclusion/NN
of/IN
counted/JJ
GRS/NN
or/CC
weighted/JJ
GRS/NN
revealed/VBD
improved/VBD
estimates/NNS
of/IN
CRC/NN
prediction/NN
beyond/IN
that/DT
provided/VBD
by/IN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
age/NN
and/CC
family/NN
history/NN
of/IN
CRC/NN
./.
====================
For/IN
example/NN
,/,
when/WRB
counted/VBN
GRS/NN
were/VBD
added/VBN
to/TO
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
consisting/VBG
of/IN
age/NN
and/CC
family/NN
history/JJ
of/IN
CRC/NN
,/,
the/DT
AUC/NN
increased/VBD
by/IN
4.2/CD
%/NN
in/IN
men/NNS
and/CC
5.2/CD
%/NN
in/IN
women/NNS
,/,
whereas/IN
the/DT
AUC/NN
increased/VBD
by/IN
3.2/CD
%/NN
in/IN
men/NNS
and/CC
4.8/CD
%/NN
in/IN
women/NNS
when/WRB
weighted/VBN
GRS/NN
were/VBD
added/VBN
to/TO
the/DT
same/JJ
model/NN
./.
====================
Studies/NNS
showing/VBG
significant/JJ
relationships/NNS
of/IN
GRS/NN
in/IN
conjunction/NN
with/IN
coronary/JJ
heart/NN
disease/NN
,/,
type/NN
2/CD
diabetes/NNS
,/,
and/CC
breast/NN
cancer/NN
have/VBP
reported/VBN
that/IN
considering/VBG
the/DT
contribution/NN
of/IN
multiple/JJ
SNPs/NNS
may/MD
improve/VB
the/DT
predictive/JJ
value/NN
of/IN
GRS/NN
for/IN
such/JJ
diseases/NNS
[/(
18/CD
,/,
31/CD
,/,
45/CD
]/)
./.
====================
In/IN
other/JJ
words/NNS
,/,
combining/VBG
multiple/JJ
loci/NNS
with/IN
modest/JJS
effects/NNS
into/IN
a/DT
global/JJ
GRS/NN
might/MD
improve/VB
identification/NN
of/IN
persons/NNS
who/WP
are/VBP
at/IN
risk/NN
for/IN
such/JJ
diseases/NNS
[/(
23-25/CD
]/)
./.
====================
For/IN
example/NN
,/,
in/IN
the/DT
ARIC/NN
study/NN
,/,
the/DT
contribution/NN
of/IN
multiple/JJ
SNPs/NNS
into/IN
a/DT
single/JJ
GRS/NN
was/VBD
responsible/JJ
for/IN
an/DT
improvement/NN
in/IN
the/DT
prediction/NN
of/IN
incident/JJ
CHD/NN
[/(
18/CD
]/)
./.
====================
In/IN
a/DT
study/NN
that/IN
used/VBN
counted/VBN
GRS/NN
or/CC
weighted/JJ
GRS/NN
to/TO
determine/VB
the/DT
risk/NN
for/IN
type/NN
2/CD
diabetes/VBZ
in/IN
US/NN
men/NNS
and/CC
women/NNS
,/,
individuals/NNS
in/IN
the/DT
highest/JJS
quintile/RB
of/IN
GRS/NN
had/VBD
a/DT
significantly/RB
increased/VBD
risk/NN
of/IN
type/NN
2/CD
diabetes/VBZ
compared/VBN
to/TO
those/DT
in/IN
the/DT
lowest/JJ
quintile/RB
;/:
however/RB
,/,
the/DT
addition/NN
of/IN
GRS/NN
increased/VBD
the/DT
AUC/NN
by/IN
only/RB
1/CD
%/NN
./.
====================
In/IN
this/DT
instance/NN
,/,
the/DT
GRS/NN
was/VBD
determined/VBN
to/TO
be/VB
useful/JJ
when/WRB
combined/VBN
with/IN
the/DT
joint/NN
effects/NNS
of/IN
BMI/NN
and/CC
counted/VBN
GRS/NN
or/CC
family/NN
history/NN
of/IN
diabetes/NNS
and/CC
counted/VBN
GRS/NN
[/(
30/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
individuals/NNS
in/IN
the/DT
highest/JJS
quartile/JJ
of/IN
GRS/NN
had/VBD
increased/VBN
risk/NN
of/IN
CRC/NN
compared/VBN
to/TO
those/DT
in/IN
the/DT
lowest/JJS
quartile/RB
of/IN
GRS/NN
for/IN
both/DT
men/NNS
and/CC
women/NNS
./.
====================
In/IN
addition/NN
,/,
in/IN
strata/JJ
of/IN
family/NN
history/NN
of/IN
CRC/NN
and/CC
GRS/NN
,/,
this/DT
increase/NN
was/VBD
even/RB
higher/JJR
in/IN
individuals/NNS
with/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
in/IN
the/DT
highest/JJS
quartile/RB
of/IN
GRS/NN
compared/VBN
to/TO
those/DT
without/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
in/IN
the/DT
highest/JJS
quartile/RB
of/IN
GRS/NN
in/IN
both/DT
men/NNS
and/CC
women/NNS
./.
====================
Still/RB
,/,
there/EX
were/VBD
statistically/RB
significant/JJ
interactions/NNS
in/IN
men/NNS
but/CC
not/RB
in/IN
women/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
the/DT
most/JJS
commonly/RB
used/VBN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
smoking/JJ
and/CC
alcohol/NN
consumption/NN
,/,
were/VBD
also/RB
not/RB
included/VBD
in/IN
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
,/,
as/IN
smoking/JJ
,/,
alcohol/NN
consumption/NN
,/,
BMI/NNP
,/,
and/CC
WC/NN
did/VBD
not/RB
significantly/RB
interact/VB
with/IN
the/DT
GRS/NN
./.
====================
Therefore/RB
,/,
further/RBR
studies/NNS
are/VBP
needed/VBN
to/TO
verify/VB
these/DT
results/NNS
./.
====================
A/DT
family/NN
history/NN
of/IN
CRC/NN
is/VBZ
commonly/RB
used/VBN
as/IN
a/DT
surrogate/NN
marker/NN
for/IN
determining/VBG
genetic/JJ
susceptibility/NN
to/TO
CRC/NN
and/CC
remains/VBZ
one/CD
of/IN
the/DT
strongest/JJS
risk/NN
factors/NNS
for/IN
the/DT
disease/NN
[/(
10/CD
,/,
31/CD
,/,
46/CD
]/)
./.
====================
Approximately/RB
25/CD
%/NN
of/IN
all/DT
CRC/NN
cases/NNS
occur/VBP
in/IN
individuals/NNS
with/IN
a/DT
family/NN
history/NN
of/IN
the/DT
disease/NN
and/CC
no/DT
genetic/JJ
disorders/NNS
[/(
47/CD
]/)
./.
====================
In/IN
addition/NN
,/,
some/DT
retrospective/JJ
studies/NNS
have/VBP
suggested/VBN
that/IN
a/DT
history/JJ
of/IN
CRC/NN
in/IN
a/DT
first-degree/JJ
relative/JJ
(/(
a/DT
parent/JJ
or/CC
sibling/NN
)/)
elevates/VBZ
a/DT
person/NN
's/POS
lifetime/JJ
risk/NN
of/IN
CRC/NN
from/IN
1.8-fold/JJ
to/TO
8.0-fold/JJ
[/(
10/CD
,/,
47/CD
]/)
./.
====================
This/DT
family/NN
history/NN
risk/NN
factor/NN
may/MD
encompass/VB
both/CC
genetic/JJ
and/CC
shared/JJ
environmental/JJ
components/NNS
[/(
31/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
after/IN
controlling/VBG
for/IN
age/NN
and/CC
GRS/NN
,/,
the/DT
strong/JJ
relationship/NN
between/IN
family/NN
history/NN
of/IN
CRC/NN
and/CC
risk/NN
of/IN
CRC/NN
persisted/VBD
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
other/JJ
risk/NN
loci/NNS
remain/VBP
to/TO
be/VB
discovered/VBN
or/CC
that/DT
family/NN
history/NN
has/VBZ
a/DT
much/RB
larger/JJR
shared/JJ
environmental/JJ
component/NN
than/IN
previously/RB
thought/VBN
[/(
31/CD
]/)
./.
====================
Our/PRP$
study/NN
was/VBD
not/RB
without/IN
limitations/NNS
./.
====================
The/DT
cross-sectional/JJ
design/NN
precluded/VBD
the/DT
determination/NN
of/IN
causality/NN
,/,
and/CC
a/DT
prevalent/JJ
case/NN
bias/NNS
may/MD
exist/VB
due/IN
to/TO
the/DT
higher/JJR
number/NN
of/IN
prevalent/JJ
cases/NNS
(/(
n/NN
=/JJ
165/CD
)/)
of/IN
CRC/NN
included/VBD
compared/VBN
to/TO
the/DT
number/NN
of/IN
incident/JJ
cases/NNS
(/(
n/NN
=/JJ
22/CD
)/)
./.
====================
Combining/VBG
prevalence/NN
and/CC
incidence/NN
cases/NNS
could/MD
introduce/VB
survival/NN
biases/VBZ
./.
====================
Still/RB
,/,
the/DT
5-year/JJ
survival/NN
rate/NN
for/IN
CRC/NN
in/IN
Koreans/NNS
was/VBD
71.3/CD
%/NN
in/IN
2009/CD
while/IN
that/DT
in/IN
Americans/NNS
,/,
Europeans/NNS
,/,
and/CC
Japanese/JJ
was/VBD
65.0/CD
%/NN
,/,
56.2/CD
%/NN
,/,
and/CC
65.2/CD
%/NN
,/,
respectively/RB
[/(
43/CD
]/)
./.
====================
It/PRP
could/MD
be/VB
said/VBN
that/DT
Koreans/NN
have/VBP
higher/JJR
survival/NN
rates/NNS
for/IN
CRC/NN
compared/VBN
to/TO
other/JJ
ethnic/JJ
populations/NNS
./.
====================
Additionally/RB
,/,
this/DT
study/NN
is/VBZ
also/RB
a/DT
case-cohort/JJ
study/NN
./.
====================
Blood/NN
samples/NNS
of/IN
prevalent/JJ
cases/NNS
used/VBN
in/IN
this/DT
study/NN
were/VBD
from/IN
baseline/NN
,/,
and/CC
incidence/NN
cases/NNS
during/IN
the/DT
follow-up/JJ
period/NN
,/,
suggested/VBD
as/IN
prevalent/JJ
cases/NNS
in/IN
this/DT
study/NN
,/,
might/MD
have/VBP
been/VBN
missed/VBN
,/,
as/IN
other/JJ
blood/NN
samples/NNS
were/VBD
not/RB
taken/VBN
./.
====================
Therefore/RB
,/,
those/DT
prevalent/JJ
cases/NNS
at/IN
baseline/NN
might/MD
have/VB
become/VBN
incident/JJ
cases/NNS
or/CC
mortality/NN
cases/NNS
during/IN
the/DT
follow-up/JJ
period/NN
./.
====================
It/PRP
is/VBZ
hard/VBN
to/TO
say/VB
if/IN
this/DT
study/NN
was/VBD
performed/VBN
among/IN
survivors/NNS
./.
====================
Another/DT
limitation/NN
included/VBD
a/DT
self-reported/JJ
family/NN
history/NN
of/IN
CRC/NN
,/,
thus/RB
precluding/VBG
the/DT
definitive/JJ
exclusion/NN
of/IN
potential/JJ
misclassifications/NNS
./.
====================
The/DT
statistical/JJ
power/JJR
of/IN
the/DT
current/JJ
study/NN
might/MD
be/VB
too/RB
low/JJ
,/,
as/IN
genotyping/VBG
was/VBD
performed/VBN
separately/RB
for/IN
men/NNS
and/CC
women/NNS
./.
====================
In/IN
addition/NN
,/,
performing/VBG
multiple/JJ
tests/NNS
separately/RB
in/IN
both/CC
men/NNS
and/CC
women/NNS
may/MD
increase/VB
error/IN
rates/NNS
./.
====================
Although/IN
CRC/NN
affects/VBZ
men/NNS
and/CC
women/NNS
equally/RB
,/,
gender/NN
differences/NNS
in/IN
CRC/NN
may/MD
exist/VB
./.
====================
For/IN
example/NN
,/,
regarding/VBG
colorectal/JJ
polyps/NNS
and/CC
tumors/NNS
,/,
men/NNS
had/VBD
a/DT
greater/JJR
risk/NN
of/IN
polyps/NNS
(/(
OR/NN
,/,
1.52/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.41/CD
to/TO
1.64/CD
)/)
and/CC
tumors/NNS
(/(
OR/NN
,/,
1.43/CD
;/:
95/CD
%/NN
CI/NN
,/,
1.22/CD
to/TO
1.68/CD
)/)
than/IN
women/NNS
./.
====================
In/IN
addition/NN
,/,
women/NNS
had/VBD
greater/JJR
number/NN
of/IN
purely/RB
right-sided/JJ
polyps/NNS
and/CC
tumor/NN
development/NN
[/(
48/CD
]/)
./.
====================
Therefore/RB
,/,
detection/NN
of/IN
genetic/JJ
effects/NNS
separately/RB
in/IN
men/NNS
and/CC
women/NNS
may/MD
be/VB
needed/VBN
./.
====================
In/IN
addition/NN
,/,
age/NN
differences/NNS
in/IN
case/NN
and/CC
control/NN
participants/NNS
may/MD
also/RB
increase/VBP
error/IN
rates/NNS
,/,
as/IN
control/JJ
participants/NNS
may/MD
become/VB
CRC/NN
patients/NNS
when/WRB
they/PRP
reach/VBP
the/DT
case/NN
age/NN
./.
====================
This/DT
study/NN
also/RB
involved/VBN
the/DT
lack/NN
of/IN
validation/NN
and/CC
replication/NN
of/IN
the/DT
current/JJ
study/NN
results/VBZ
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
hard/VBN
to/TO
say/VB
that/DT
there/EX
may/MD
have/VB
been/VBN
a/DT
true/JJ
association/NN
between/IN
GRS/NN
and/CC
CRC/NN
in/IN
Korean/JJ
men/NNS
and/CC
women/NNS
./.
====================
However/RB
,/,
bootstrapping/VBG
and/CC
10-fold/JJ
cross/JJ
validation/NN
were/VBD
used/VBN
for/IN
internal/JJ
and/CC
external/JJ
validity/NN
of/IN
this/DT
current/JJ
study/NN
./.
====================
Furthermore/RB
,/,
although/IN
sigmoidoscopy/colonoscopy/NN
history/JJ
was/VBD
the/DT
strongest/JJS
risk/NN
factor/NN
in/IN
the/DT
previous/JJ
study/NN
,/,
this/DT
current/JJ
study/NN
did/VBD
not/RB
include/VB
it/PRP
as/IN
one/CD
of/IN
the/DT
conventional/JJ
risk/NN
factors/NNS
of/IN
CRC/NN
./.
====================
Cases/NNS
included/VBD
in/IN
this/DT
study/NN
were/VBD
also/RB
relatively/RB
small/JJ
./.
====================
This/DT
study/NN
also/RB
excluded/VBN
cases/NNS
â‰¥/CD
55/CD
years/NNS
of/IN
CRC/NN
onset/NN
age/NN
to/TO
obtain/VB
early-onset/JJ
CRC/NN
cases/NNS
./.
====================
Therefore/RB
,/,
estimate/NN
effects/NNS
of/IN
cases/NNS
â‰¥/CD
55/CD
years/NNS
of/IN
CRC/NN
onset/NN
age/NN
were/VBD
hard/RB
to/TO
be/VB
seen/VBN
in/IN
this/DT
study/NN
./.
====================
Finally/RB
,/,
most/JJS
SNPs/NNS
found/VBN
to/TO
be/VB
associated/VBN
with/IN
CRC/NN
among/IN
the/DT
study/NN
population/NN
were/VBD
not/RB
similar/JJ
to/TO
those/DT
SNPs/NNS
found/VBN
in/IN
relation/NN
to/TO
CRC/NN
among/IN
other/JJ
populations/NNS
./.
====================
It/PRP
also/RB
could/MD
be/VB
due/JJ
to/TO
differences/NNS
in/IN
ethnic/JJ
population/NN
and/CC
the/DT
ages/NNS
of/IN
case/NN
participants/NNS
included/VBD
in/IN
this/DT
study/NN
(/(
cases/NNS
</JJR
55/CD
years/NNS
)/)
./.
====================
Nevertheless/RB
,/,
this/DT
relatively/RB
large-scale/JJ
study/NN
demonstrated/VBD
the/DT
effectiveness/NN
of/IN
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
using/VBG
the/DT
GRS/NN
consisting/VBG
of/IN
only/RB
SNPs/NNS
that/DT
associated/VBN
significantly/RB
with/IN
CRC/NN
and/CC
evaluated/VBD
the/DT
effects/NNS
on/IN
the/DT
risk/NN
for/IN
CRC/NN
in/IN
combination/NN
with/IN
conventional/JJ
risk/NN
factors/NNS
,/,
such/JJ
as/IN
family/RB
history/JJ
of/IN
CRC/NN
,/,
with/IN
the/DT
GRS/NN
./.
====================
Moreover/RB
,/,
the/DT
present/JJ
study/NN
included/VBD
the/DT
Korean/JJ
population/NN
,/,
whereas/IN
previous/JJ
studies/NNS
involving/VBG
CRC/NN
prediction/NN
models/NNS
using/VBG
conventional/JJ
risk/NN
factors/NNS
or/CC
the/DT
relationship/NN
of/IN
genetic/JJ
risk/NN
factors/NNS
to/TO
CRC/NN
were/VBD
limited/JJ
to/TO
white/JJ
and/CC
Japanese/JJ
populations/NNS
[/(
17/CD
,/,
20-22/NN
]/)
./.
====================
In/IN
conclusion/NN
,/,
our/PRP$
findings/NNS
suggest/VBP
that/IN
the/DT
prediction/NN
model/NN
of/IN
CRC/NN
revealed/VBD
improved/VBD
prediction/NN
estimates/NNS
when/WRB
age/NN
,/,
family/NN
history/NN
of/IN
CRC/NN
,/,
and/CC
the/DT
GRS/NN
in/IN
the/DT
Korean/JJ
population/NN
were/VBD
included/VBN
./.
====================
Furthermore/RB
,/,
when/WRB
compared/VBN
to/TO
those/DT
in/IN
the/DT
lowest/JJS
quartile/RB
of/IN
GRS/NN
in/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
,/,
the/DT
risk/NN
of/IN
CRC/NN
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
increased/VBD
in/IN
individuals/NNS
with/IN
a/DT
family/NN
history/NN
of/IN
CRC/NN
in/IN
the/DT
highest/JJS
quartile/RB
of/IN
GRS/NN
./.
====================
However/RB
,/,
it/PRP
was/VBD
statistically/RB
significant/JJ
in/IN
men/NNS
but/CC
not/RB
in/IN
women/NNS
./.
====================
Findings/NNS
in/IN
this/DT
current/JJ
study/NN
might/MD
provide/VB
a/DT
small/JJ
piece/NN
of/IN
evidence/NN
in/IN
prediction/NN
of/IN
CRC/NN
for/IN
reducing/VBG
its/PRP$
prevalence/NN
and/CC
incidence/NN
rates/NNS
./.
====================
The/DT
prediction/NN
model/NN
developed/VBD
in/IN
this/DT
study/NN
needs/VBZ
to/TO
be/VB
validated/VBN
or/CC
replicated/VBN
in/IN
an/DT
independent/JJ
population/NN
./.
====================
Therefore/RB
,/,
further/RBR
studies/NNS
are/VBP
needed/VBN
to/TO
be/VB
applied/VBN
to/TO
the/DT
general/JJ
population/NN
./.
====================
Effects/NNS
of/IN
family/NN
history/NN
of/IN
CRC/NN
and/CC
GRS/NN
on/IN
the/DT
risk/NN
of/IN
CRC/NN
in/IN
Koreans/NNS
who/WP
participated/JJ
in/IN
the/DT
KCPS-II/NN
(/(
adjusted/VBN
for/IN
age/NN
,/,
BMI/NNP
and/CC
smoking/NN
status/NN
)/)
(/(
A/DT
)/)
counted/VBN
GRS/NN
in/IN
men/NNS
and/CC
women/NNS
(/(
B/NN
)/)
weighted/VBD
GRS/NN
in/IN
men/NNS
and/CC
women/NNS
./.
====================
CRC/NN
,/,
colorectal/JJ
cancer/NN
;/:
GRS/NN
,/,
genetic/JJ
risk/NN
scores/NNS
;/:
KCPS-II/NN
,/,
Korean/JJ
Cancer/NN
Prevention/NN
Study-II/NN
;/:
BMI/NN
,/,
body/NN
mass/NN
index/NN
;/:
OR/NN
,/,
odds/NNS
ratio/NN
./.
====================
aMeans/NNS
statistically/RB
significant/JJ
./.
====================
General/JJ
characteristics/NNS
of/IN
case/NN
participants/NNS
and/CC
control/NN
participants/NNS
in/IN
KCPS-II/NN
====================
Odds/NNS
ratios/NNS
and/CC
95/CD
%/NN
confidence/NN
intervals/NNS
for/IN
colorectal/JJ
cancer/NN
using/VBG
counted/JJ
and/CC
weighted/JJ
genetic/JJ
risk/NN
score/RB
in/IN
Korean/JJ
men/NNS
and/CC
women/NNS
in/IN
KCPS-II/NN
====================
